MORGANTOWN, W.Va.

Author Amanda R. Potts is preparing to introduce young readers and families to Ray’s Summer at SandPlant, a joyful children’s book inspired by treasured summers spent camping, swimming, exploring, and making memories with loved ones.

The story follows Ray, a cheerful young girl who travels with her parents, her older sisters Dawn and Rose, and their loyal dog, Toto, to SandPlant, a place the family visits every summer. From the moment they arrive, Ray eagerly looks forward to swimming, sliding down the waterfalls, playing Marco Polo with her cousins, building sandcastles, enjoying ice cream, roasting marshmallows, and falling asleep beneath the stars.

Although the adventure is filled with fun, Ray also learns to be careful and responsible. She listens to warnings about slippery rocks, remains in shallow water when she feels unsure, watches for snakes near the swimming areas, washes her hands before meals, and follows her parents’ guidance throughout the day. These gentle lessons are woven naturally into a story centered on family connection, outdoor play, safety, and childhood confidence.

For Amanda, the book carries deeply personal meaning. SandPlant was an important summer destination for her and her sisters, and the memories they created there remained with her long after the location closed to the public. By transforming those experiences into a children’s story, Amanda hopes to preserve the happiness of those summers while encouraging other families to appreciate the simple moments they share together.

Ray’s Summer at SandPlant is intended for parents with young children and early readers who enjoy stories about family, camping, pets, nature, and summertime adventures. Its warm and relatable scenes invite children to think about their own favorite traditions and the people who make those memories special.

The forthcoming book will be released in e-book and paperback formats through Lumera Publishing. Additional publication and purchasing information will be announced closer to its official launch.

About the Author

Amanda R. Potts was born and raised in Morgantown, West Virginia. Amanda lives with her boyfriend, Travis, and their three cats, Luna, Elly, and Tobias. Becoming an author has long been one of Amanda’s greatest dreams, and Ray’s Summer at SandPlant is her first book.

Author Name: Amanda R. Potts  Book Title: Ray’s Summer at SandPlant  Book Published by: Lumera Publishing

SAN RAFAEL, California

California contractors can create more opportunities to reach local customers by making their websites, Google profiles and business information easier to find and understand online.

Mount Tam Marketing, a San Rafael-based marketing company, provides straightforward, fixed-price services designed for roofing companies, plumbers, electricians, landscapers, general contractors and other trade businesses.

The company helps contractors strengthen how they appear across Google, local directories and AI-powered search tools without requiring expensive agency packages, monthly retainers or long-term contracts.

“Many contractors already have the experience, reputation and customer reviews needed to grow,” said a Mount Tam Marketing spokesperson. “Our goal is to help make sure potential customers can clearly find their business, understand what they offer and contact them for an estimate.”

Mount Tam Marketing reviews contractor websites and online listings to identify practical opportunities such as:

• Clearly explaining services and service areas
• Improving contact forms and estimate-request options
• Correcting inconsistent phone numbers or business information
• Strengthening Google Business Profiles
• Creating direct Google review links and QR codes
• Adding useful local business listings
• Identifying credible backlink opportunities
• Improving visibility for Google and AI search tools
• Each service includes a defined scope, published price and clear list of deliverables.

The company’s Website Search Check reviews how effectively a contractor’s website communicates its services, locations and contact information. Contractors receive a practical list of recommended improvements that they can complete themselves or share with their website provider.

Mount Tam Marketing also offers press release writing and distribution for contractors announcing new services, completed projects, company milestones, certifications, expanded service areas or community involvement.

The company was created to give local businesses access to professional marketing support at a reasonable price.

Rather than selling a large marketing package, Mount Tam Marketing allows contractors to select the individual services that best fit their current needs.

California contractors interested in reaching more local customers can review available services and pricing at MountTamMarketing.com.

About Mount Tam Marketing

Mount Tam Marketing provides fixed-price marketing services for contractors and other local businesses. Based in San Rafael, California, the company helps businesses improve their websites, Google presence, online listings, customer review process and visibility across traditional and AI-powered search.

Media Contact Details
Marketing Team
Mount Tam Marketing
Email: Send Email
Website: MountTamMarketing.com

ABBOTT PARK, Ill.

Prospective post-market study will enroll approximately 1,000 patients across the United States, Canada and Europe

TriClip provides a minimally invasive treatment option for eligible patients with symptomatic tricuspid regurgitation who face increased surgical risk

Abbott (NYSE: ABT) today announced the initiation of the TREAT TR study, a prospective post-market study evaluating the safety, performance and clinical outcomes of the company’s TriClip™ transcatheter edge-to-edge repair system in real-world clinical practice.

TriClip is specifically designed to treat tricuspid regurgitation, or TR, a condition commonly known as a leaky tricuspid heart valve. The TREAT TR study will expand the body of clinical evidence supporting the system and assess its performance across a diverse population of patients, healthcare centers and geographic regions.

The first patient in the study was enrolled at Hospital Clínic de Barcelona in Spain by Xavier Freixa, M.D., and his cardiac team.

Study to Enroll Approximately 1,000 Patients

The prospective, observational, single-arm, multicenter study is expected to enroll approximately 1,000 patients at as many as 100 clinical sites in the United States, Canada and Europe.

Participants will be evaluated at hospital discharge, 30 days, six months and one year following treatment. Annual follow-up assessments will then continue for an additional four years, providing five years of clinical information for each participating patient.

A selected group of patients will also participate in a sub-study examining whether treatment with TriClip may reverse cardiac remodeling—the structural changes that can occur when the heart is injured or subjected to prolonged pressure or volume overload.

“Prior to TriClip’s availability, many patients with tricuspid regurgitation had few treatment options because medical therapy didn’t relieve their symptoms or they were at an increased risk for conventional open-heart surgery,” said Anita Asgar, M.D., section head of interventional cardiology and medical director for the Bluhm Cardiovascular Institute Structural Heart Program at Northwestern Medicine in Chicago and co-principal investigator of the TREAT TR study.

“Through multiple clinical studies and in working directly with patients, we’ve seen that TriClip can have a profound impact on the lives of people with TR, and we’re excited to see additional evidence to support this minimally invasive device.”

Addressing Tricuspid Regurgitation

The tricuspid valve controls blood flow from the heart’s right atrium to its right ventricle. Tricuspid regurgitation occurs when the valve does not close properly, allowing blood to flow backward through the valve.

The condition can force the heart to work harder and may cause symptoms including fatigue, swelling and shortness of breath. When left untreated, severe TR may contribute to complications such as atrial fibrillation and heart failure.

TriClip is intended to provide an additional treatment option for eligible patients who remain symptomatic despite medical therapy and are considered to be at elevated risk for conventional open-heart surgery.

The system’s transcatheter edge-to-edge repair technology is delivered through a vein in the leg. It works by clipping together portions of the tricuspid valve leaflets, helping the valve close more effectively and reducing backward blood flow without requiring open-heart surgery.

Patients treated with TriClip spend an average of approximately one day in the hospital following the procedure before returning home.

Clinical Evidence Supports TriClip Treatment

TriClip has been evaluated through several clinical studies, including the TRILUMINATE Pivotal trial. Results from the trial demonstrated that the system reduced the severity of tricuspid regurgitation, improved patients’ quality of life and supported reductions in heart-failure-related hospitalizations.

Findings from the TRILUMINATE Pivotal trial supported approval of the TriClip system by the U.S. Food and Drug Administration.

Additional real-world evidence was presented in June 2026 at the New York Valves conference. The analysis included 3,035 patients recorded in the Society of Thoracic Surgeons and American College of Cardiology Transcatheter Valve Therapy Registry across 278 clinical sites in the United States.

The registry findings showed outcomes consistent with those observed in the TRILUMINATE Pivotal trial, including meaningful reductions in TR severity and improvements in patients’ quality of life.

“Clinical studies have continued to reinforce the benefits of repairing the tricuspid valve with TriClip and the significant improvements that it brings to people’s daily lives, including reducing the rate of hospitalizations due to heart failure,” said Lars Sondergaard, M.D., chief medical officer of Abbott’s structural heart business.

“We believe the TREAT TR study will further confirm TriClip’s safety profile and effectiveness in reducing tricuspid regurgitation across a diverse range of patients and locations.”

About the TREAT TR Study

TREAT TR is a prospective, observational, single-arm, multicenter post-market study designed to evaluate the safety and real-world performance of the TriClip system.

The study will build upon existing clinical evidence and assess patient outcomes across a broader range of clinical environments, populations and geographic locations.

About TriClip™

TriClip is a minimally invasive treatment option designed to repair the tricuspid valve through transcatheter edge-to-edge repair.

The system has been approved for use in more than 50 countries, including the United States, Canada and countries across Europe, since receiving its initial CE Mark approval in 2020. TriClip has been used to treat more than 15,000 people with tricuspid regurgitation.

For important U.S. safety information regarding TriClip, visit:

https://abbo.tt/TriClip_ISI

About Abbott

Abbott (NYSE: ABT) is a global healthcare company that develops technologies designed to help people live more fully throughout all stages of life.

The company’s portfolio includes products and services across diagnostics, medical devices, nutrition and branded generic medicines. Abbott employs approximately 122,000 people and serves customers in more than 160 countries.

For additional information, visit Abbott.com.

Media Contact Details
Abbott Team
Abbott
Email: Send Email